Wipfli Financial Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Wipfli Financial Advisors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4K	Buy	+53	New	+$3.14K	﹤0.01%	2117

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Wipfli Financial Advisors's APLS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2022: 53 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #2117 among its holdings.

250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

Wipfli Financial Advisors held 53 shares of Apellis Pharmaceuticals worth $4K as of Q3 2022.
Apellis Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Apellis Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2117 holding.
250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.